Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO David P. Schenkein sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $61.55, for a total value of $369,300.00. Following the completion of the transaction, the chief executive officer now owns 6,000 shares in the company, valued at $369,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) traded down $0.93 during midday trading on Tuesday, reaching $61.33. The company’s stock had a trading volume of 301,294 shares, compared to its average volume of 512,803. Agios Pharmaceuticals, Inc. has a 52 week low of $39.24 and a 52 week high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. The company had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.63) earnings per share. equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.59 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in shares of Agios Pharmaceuticals by 14.1% during the second quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares during the period. Vanguard Group Inc. increased its position in shares of Agios Pharmaceuticals by 23.8% during the second quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares during the period. Capital International Investors increased its position in shares of Agios Pharmaceuticals by 0.3% during the third quarter. Capital International Investors now owns 3,138,131 shares of the biopharmaceutical company’s stock worth $209,470,000 after acquiring an additional 8,294 shares during the period. BB Biotech AG increased its position in shares of Agios Pharmaceuticals by 1.1% during the second quarter. BB Biotech AG now owns 2,869,528 shares of the biopharmaceutical company’s stock worth $147,637,000 after acquiring an additional 30,000 shares during the period. Finally, BlackRock Inc. increased its position in shares of Agios Pharmaceuticals by 23.5% during the second quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock worth $137,648,000 after acquiring an additional 508,306 shares during the period. 94.38% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts recently commented on AGIO shares. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 target price on the stock. Credit Suisse Group boosted their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Finally, SunTrust Banks reissued a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $75.70.

TRADEMARK VIOLATION WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/05/insider-selling-agios-pharmaceuticals-inc-agio-ceo-sells-6000-shares-of-stock.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.